Since then, we have provided comprehensive evidence that the glycome of more aggressive tumors becomes enriched in immature O-glycans, such as the Tn and STn antigens, which, due to their cancer-specific nature, hold potential for patient stratification and therapeutic development [14,36]. The gene discussed is EEF1A2; the disease is cancer.